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Objectives
To evaluate whether etravirine (TMC125) might be effective in patients failing therapy with current
nonnucleoside reverse transcriptase inhibitors (NNRTIs), we analysed the prevalence of TMC125
mutations and the possible determinants of genotypic resistance to this drug among sequences
reported to a large database in Italy [Antiretroviral Resistance Cohort Analysis (ARCA)].
Methods
We analysed the prevalence of TMC125 resistance-associated mutations (RAMs) and the TMC125
weighted genotypic score (WGS) together with the determinants of genotypic resistance. A total of
5011 sequences from 2955 patients failing NNRTI therapy were evaluated.
Results
Among the sequences in ARCA, 68% had at least one and 9.8% at least three TMC125 RAMs,
whereas 31% had a WGS42. Frequent RAMs were Y181C, G190A, K101E and A98G, whereas V179F,
Y181V and G190S appeared in o5% of sequences. Multivariate analysis revealed a higher risk of
developing at least three TMC125 RAMs associated with both nevirapine and efavirenz exposure,
whereas CD4 counts  200 cells/mL retained their protective effect. An increased risk of WGS42
was linked to higher HIV RNA values (maximum risk at 45 log10 copies/mL) and nevirapine
exposure; CD4 counts  200 cells/mL were protective.
Conclusions
The prevalence of TMC125 resistance mutations in the ARCA cohort was 68%. The DUET studies
showed that at least three TMC125-associated mutations were required to impair the efficacy of the
drug and Y181C/V, V179F and G190S had the greatest effect on response. The prevalence of these
mutations among the patients examined in our study was low. However, WGS42 was found for
one-third of our sequences. Previous nevirapine exposure was associated with an increased risk of
having WGS42 (adjusted odds ratio 1.76).
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Introduction
HIV-infected patients who experience triple-drug class
virological failure may be at increased risk of clinical
progression and death [1]. Therefore, newer agents with
activity against drug-resistant HIV-1 are needed [2].
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Etravirine (TMC125) is a second-generation nonnucleo-
side reverse transcriptase inhibitor (NNRTI) with potent
activity against wild-type and NNRTI-resistant HIV-1 and a
high genetic barrier to the development of resistance [3,4];
its potent antiretroviral activity has been demonstrated in
the phase III DUET studies [5,6].
Information on TMC125 resistance is still scarce: a set of
13 baseline reverse transcriptase mutations was previously
identified in the DUET studies as having an effect on
virological response to TMC125 [7–12]. Poveda et al. [12]
suggested that efavirenz (EFV) might be less capable of
inducing TMC125 resistance than nevirapine (NVP). More-
over, a longer duration of initial NNRTI treatment has been
associated with increased evidence of in vitro TMC125
resistance [13] and the inclusion of NVP within the initial
highly active antiretroviral therapy (HAART) regimen
could result in a higher risk of virological failure and drug
resistance compared with EFV [14]. This could limit the
future use of TMC125 [15].
Recently, Tambuyzer et al. examined two TMC125
weighted genotypic scores (WGSs) [TBT (Tibotec, Mechelen,
Belgium) and MGR (Monogram, San Francisco, CA, USA)],
which produced similar results in defining susceptibility to
TMC125 in treatment-experienced patients and were able
to predict nonresponse to TMC125 in  60% of subjects
enrolled in the DUET trials [16]. Nevertheless, there is a
difference between mutations associated with TMC125 use
(L100I, E138G, V179F/I, Y181C/I and H221Y), i.e. muta-
tions that emerge with use of TMC125, and mutations
associated with an altered response to TMC125 (V90I,
A98G, L100I, K101E/H/P, V106I, E138A, V179D/T/F,
Y181C/I/V and G190A/S).
To evaluate whether etravirine might be effective in
patients failing therapy with current NNRTIs, we analysed
the prevalence of etravirine mutations and possible
determinants of genotypic resistance to this drug among
sequences reported to a large Italian database.
Materials and methods
We retrospectively considered HIV-1 reverse transcriptase
sequences obtained from the Italian Antiretroviral Resis-
tance Cohort Analysis (ARCA; available at www.hivarca.net)
database for a total of 2955 patients experiencing therapy
failure with an NNRTI-based regimen at the time of blood
drawing, and with complete treatment history available.
These subjects had been selected on the basis of having a
resistance test while failing their antiretroviral regimen
(viral load41000 HIV-1 RNA copies/mL). Patients were
TMC125-naı¨ve. Inclusion criteria were NNRTI-based regi-
men for at least 3 months, and an HIV RNA measurement
and CD4 cell count available within 1 month.
Drug resistance mutations were interpreted following the
latest International AIDS Society-USA (IAS-USA) panel list
of mutations proposed to be TMC125-specific (www.iasusa.
org; update in December 2008) [17]: V90I, A98G, L100I,
K101E, K101P, K101H, V106I, E138A, V179D, V179F,
V179T, Y181C, Y181I, Y181V, G190A, G190S and M230L.
Given the high prevalence of mutation K103N among
isolates resistant to other NNRTIs, we also added this
mutation to our analysis.
The risk of developing at least three TMC125 resistance-
associated mutations (RAMs) [7,8] was assessed by means
of binary logistic regressions models. Univariate and
multivariate analyses were performed to estimate crude
and adjusted relative risks (odds ratios, 95% confidence
intervals and Wald statistic) for gender, age, HIV RNA, CD4
cell count; and NVP, EFV, protease inhibitor (PI) and
enfuvirtide (T20) exposure. Moreover, we considered the
number of NNRTIs received and the duration of NNRTI
therapy. The level of statistical significance was set at
P5 0.05. SPSS 15 for Windows was the statistical software
package used for the analyses (SPSS, Chicago, IL, USA).
Moreover, we conducted our analysis with the endpoint
of having a TBT WGS42, which has been reported to
predict poor virological response to TMC125 in treatment-
experienced patients [16].
Results
A total of 5011 sequences obtained from 2955 patients were
evaluated. Of these, 1241 subjects (42.0%) were exposed
only to NVP, 1053 (35.6%) only to EFV, and 613 (20.7%) to
both NVP and EFV.
Of these 2955 patients, 2153 (72.9%) presented with at
least one TMC125 RAM. Among the sequences in ARCA,
68% had at least one and 9.8% at least three TMC125
RAMs, whereas 31% showed a WGS42.
Among the samples with at least one RAM for TMC125
(n5 3407), the mutations most frequently represented were
Y181C (27%), G190A (22.8%), K101E (11.7%) and A98G
(9.3%). K103N was present in 53.9% of sequences. V179F,
Y181V and G190S were present in 0.3%, 1.0% and 4.9% of
sequences, respectively. When at least three TMC125-
related mutations were found (n5 495), the mutations
most frequently represented were G190A (62%), Y181C
(57.6%) and K101E (44%). K103N was present in 44.8% of
sequences. V179F, Y181V and G190S were present in 1.4%,
1.0% and 13.5% of sequences, respectively (Fig. 1). Among
the samples with TBT WGS42 (n5 1553), the most
frequent mutations were Y181C (59.3%), G190A (26.7%)
and K101E (17.8%); K103N was found in 40.1% of
sequences.
2 P Di Vincenzo et al.
r 2010 British HIV Association HIV Medicine (2010)
We also analysed the association between TMC125 RAMs
and exposure to NVP and EFV: these mutations appeared
more frequently in NVP- than EFV-treated patients: 90.2%
of sequences from patients exposed to NVP vs. 35.2% of
sequences from patients exposed to EFV had mutation
Y181C, and these percentages were, respectively, 84.7% vs.
43.1% for G190A, 72.7% vs. 49.8% for K101E, 100% vs.
23.5% for Y181V, and 66.7% vs. 33.3% for V179F. G190S
appeared more frequently with exposure to EFV (81.4% of
sequences) than NVP (43.3% of sequences).
Multivariate analysis revealed that male gender and
being EFV- or NVP-experienced were associated with
statistically significant increases in the risk of developing
three or more TMC125 RAMs. CD4 values  200 cells/mL
and greater age (for each additional 10 years) were
statistically protective factors, whereas PI and T20 experi-
ence and HIV RNA values did not show any statistically
significant associations. Considering the duration of NNRTI
treatment, every additional year of therapy represented a
slightly increased risk of developing at least three TMC125
RAMs, although this was not statistically significant; also,
being exposed to two NNRTIs, but not to one, produced an
adjusted odds ratio (AOR) of 1.93 (95% CI 0.74–5.07).
We then focused our attention on the risk of having a
TBT WGS42. As shown in Table 1, some differences were
found in comparison to the analysis of at least three
TMC125 RAMs. Of interest, a strong predictor of a
decreased phenotypic susceptibility to TMC125 was a
higher HIV RNA value (maximum risk at 45 log10
copies/mL), with the AOR increasing from 2.62 for HIV
RNA (o3.7 log10 copies/mL; 95% CI 1.35–5.10; P5 0.004)
to 3.99 for HIV RNA (45 log10 copies/mL; 95% CI 1.98–
8.04; Po0.001). NVP exposure retained an increased risk of
a TBT WGS42 (AOR 1.76; 95% CI 1.42–2.18; Po0.001),
whereas previous EFV treatment did not. Duration of
NNRTI therapy and previous exposure to one NNRTI did
not have any significant effect, whereas exposure to two
NNRTIs still had a significant effect, with an AOR of 2.26
(95% CI 1.05–4.88; P5 0.038).
Conclusions
The prevalence of TMC125-related mutations in the ARCA
cohort was 68%. According to the DUET studies [7,8],
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Fig. 1 Drug resistance mutations were interpreted following the
latest International AIDS Society-USA (IAS-USA) panel list of
mutations proposed to be etravirine (TMC125)-specific (www.iasusa.
org; update in December 2008) [17]. There were 3407 sequences
with at least one TMC125 resistance-associated mutation (RAM) and
495 sequences with at least three TMC125 RAMs. Mutation K103N
was pictured as reference NNRTIs resistance mutation.
Table 1 Determinants of genotypic resistance [Tibotec (TBT) score 0–2 or42] to TMC125
Category TBT score 0–2 TBT score42 AOR 95% CI P
Age (years) 42.8 (42) 41.4 (40) 0.80 (0.72–0.88) o0.001
Sex Female 504 (65.6) 264 (34.4) 1
Male 1168 (62.2) 698 (37.4) 1.26 (1.05–1.51) 0.015
CD4 count o200 cells/mL* 298 (56.4) 230 (43.6) 1
200–399 cells/mL 408 (66.7) 204 (33.3) 0.70 (0.54–0.90) 0.005
 400 cells/mL 450 (71.4) 180 (28.6) 0.57 (0.44–0.74) o0.001
ND 516 (59.7) 348 (40.3) 0.99 (0.76–1.29) 0.964
HIV RNA o0.7 log10 copies/mL* 69 (86.3) 11 (13.8) 1
o3.7 log10 copies/mL 476 (69.8) 206 (30.2) 2.62 (1.35–5.10) 0.004
3.7–5 log10 copies/mL 585 (60.5) 382 (39.5) 3.67 (1.90–7.10) o0.001
45 log10 copies/mL 138 (54.5) 115 (45.5) 3.99 (1.98–8.04) o0.001
ND 404 (62.2) 248 (38.0) 2.92 (1.49–5.71) 0.002
EFV-experienced 1008 (66.7) 504 (33.3) 0.96 (0.78–1.17) 0.665
NVP-experienced 974 (58.5) 690 (41.5) 1.76 (1.42–2.18) o0.001
PI-experienced 1325 (62.7) 789 (37.3) 1.10 (0.89–1.37) 0.369
T20-experienced 54 (66.7) 27 (33.3) 0.73 (0.45–1.19) 0.207
This multivariate analysis was conducted with the endpoint of having a TBT score 4 2.
Values in the TBT score columns are n (%), with the exception of mean (median) for age. AOR for age is for each additional 10 years.
*Reference category.
AOR, adjusted odds ratio; CI, confidence interval; ND, not determined; EFV, efavirenz; NVP, nevirapine; PI, protease inhibitor; T20, enfuvirtide.
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Y181C, G190A, K101E and A98G were the mutations more
frequently represented. The DUET studies showed that at
least three TMC125-associated mutations were required to
impair the efficacy of the drug [7,8]. In our cohort, only
9.8% of sequences showed at least three TMC125-
associated mutations, suggesting that the existence of this
condition is infrequent even in patients with evidence of
resistance to the other NNRTIs. V179F, Y181V and G190S,
which have the most pronounced effect on the response,
were present in o5% of sequences. When at least three
TMC125 RAMs were present, the mutations most fre-
quently represented were confirmed to be Y181C, G190A
and K101E, but not A98G. In this setting, the prevalence of
V179F, Y181C and G190S also increased.
Y181C, a common mutation which confers resistance to
other NNRTIs and to TMC125 when associated with two or
more TMC125 RAMs and which was highly prevalent
(32.2%) in the Tibotec data set [16], was associated with at
least two mutations in a higher percentage of sequences in
this study than found in the DUET studies (27% vs. 15%,
respectively) [7], but it was present with V179F and G190S
in o5% of sequences. The association of Y181C with
G190A, K101E and A98G was statistically significant. The
prevalence of V179F was low, but when associated with at
least two mutations was present in 57% of sequences and
was associated most frequently with Y181C, but was never
associated with G190S or Y181V. Y181V and G190S, the
other mutations with a large impact on response, were
associated with at least two mutations in a low percentage
of sequences.
The multivariate analysis of determinants of TBT
WGS42 demonstrated a protective effect of higher CD4
counts and a negative effect of higher HIV-RNA values, as
expected. The use of EFV resulted in less NNRTI resistance
than did the use of NVP. The pattern of resistance
mutations suggests that subsequent virological suppression
with TMC125-containing regimens may be more successful
if previous treatments included EFV rather than NVP. The
difference between exposure to NVP and EFV might be
relevant in resource-limited settings where NVP is often
used. The long-term use of NVP without optimized
nucleoside reverse transcriptase inhibitor (NRTI) back-
ground therapy could lead to an accumulation of resistance
mutations. This is of particular relevance in situations
where second-line HAART regimens are difficult to obtain.
The use of both NNRTIs, rather than the duration of
NNRTI exposure, had an impact on the occurrence of TBT
WGS42. As many HIV-positive patients still initiate
therapy with an NNRTI, it is particularly important to take
this evidence into consideration. Of note, lower CD4 counts
(o200 cells/mL) and higher HIV RNA loads (43.7 log10
copies/mL) were related to a greater risk of a TBT score42.
The judicious examination of subjects’ therapeutic
histories and the use of TBT WGS were found to be
effective in predicting resistance to TMC125. The adoption
of such tools is recommended for evaluating new
antiretrovirals for clinical use.
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